CH445129A
(en)
|
1964-04-29 |
1967-10-15 |
Nestle Sa |
Process for the preparation of high molecular weight inclusion compounds
|
US3459731A
(en)
|
1966-12-16 |
1969-08-05 |
Corn Products Co |
Cyclodextrin polyethers and their production
|
US3426011A
(en)
|
1967-02-13 |
1969-02-04 |
Corn Products Co |
Cyclodextrins with anionic properties
|
US3453257A
(en)
|
1967-02-13 |
1969-07-01 |
Corn Products Co |
Cyclodextrin with cationic properties
|
US3453259A
(en)
|
1967-03-22 |
1969-07-01 |
Corn Products Co |
Cyclodextrin polyol ethers and their oxidation products
|
US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
US5521063A
(en)
|
1985-03-15 |
1996-05-28 |
Antivirals Inc. |
Polynucleotide reagent containing chiral subunits and methods of use
|
AU5661386A
(en)
|
1985-03-15 |
1986-10-13 |
Stirchak, E. |
Stereoregular polynucleotide-binding polymers
|
US5166315A
(en)
|
1989-12-20 |
1992-11-24 |
Anti-Gene Development Group |
Sequence-specific binding polymers for duplex nucleic acids
|
US5034506A
(en)
|
1985-03-15 |
1991-07-23 |
Anti-Gene Development Group |
Uncharged morpholino-based polymers having achiral intersubunit linkages
|
US5217866A
(en)
|
1985-03-15 |
1993-06-08 |
Anti-Gene Development Group |
Polynucleotide assay reagent and method
|
US5506337A
(en)
|
1985-03-15 |
1996-04-09 |
Antivirals Inc. |
Morpholino-subunit combinatorial library and method
|
US4737323A
(en)
|
1986-02-13 |
1988-04-12 |
Liposome Technology, Inc. |
Liposome extrusion method
|
US5525465A
(en)
|
1987-10-28 |
1996-06-11 |
Howard Florey Institute Of Experimental Physiology And Medicine |
Oligonucleotide-polyamide conjugates and methods of production and applications of the same
|
US5087617A
(en)
|
1989-02-15 |
1992-02-11 |
Board Of Regents, The University Of Texas System |
Methods and compositions for treatment of cancer using oligonucleotides
|
US5670617A
(en)
|
1989-12-21 |
1997-09-23 |
Biogen Inc |
Nucleic acid conjugates of tat-derived transport polypeptides
|
KR0166088B1
(en)
|
1990-01-23 |
1999-01-15 |
. |
Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
|
US5714331A
(en)
|
1991-05-24 |
1998-02-03 |
Buchardt, Deceased; Ole |
Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
|
US5539082A
(en)
|
1993-04-26 |
1996-07-23 |
Nielsen; Peter E. |
Peptide nucleic acids
|
US5719262A
(en)
|
1993-11-22 |
1998-02-17 |
Buchardt, Deceased; Ole |
Peptide nucleic acids having amino acid side chains
|
GB9209032D0
(en)
|
1992-04-25 |
1992-06-10 |
Ciba Geigy Ag |
New peptide derivatives
|
EP0786522A2
(en)
|
1992-07-17 |
1997-07-30 |
Ribozyme Pharmaceuticals, Inc. |
Enzymatic RNA molecules for treatment of stenotic conditions
|
NZ255831A
(en)
|
1992-08-21 |
1997-04-24 |
Biogen Inc |
Fusion proteins comprising biologically active cargo moiety and transport peptides from the hiv tat protein, their preparation and use
|
CZ172395A3
(en)
|
1993-01-07 |
1996-03-13 |
Univ Jefferson |
Oligonucleotide and the use thereof
|
CN1123038A
(en)
|
1993-05-11 |
1996-05-22 |
北卡罗来纳大学查珀尔希尔分校 |
Antisense oligonucleotides which combat aberrant splicing and methods of using the same
|
US5885613A
(en)
|
1994-09-30 |
1999-03-23 |
The University Of British Columbia |
Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
|
US5753613A
(en)
|
1994-09-30 |
1998-05-19 |
Inex Pharmaceuticals Corporation |
Compositions for the introduction of polyanionic materials into cells
|
US5820873A
(en)
|
1994-09-30 |
1998-10-13 |
The University Of British Columbia |
Polyethylene glycol modified ceramide lipids and liposome uses thereof
|
IL115849A0
(en)
|
1994-11-03 |
1996-01-31 |
Merz & Co Gmbh & Co |
Tangential filtration preparation of liposomal drugs and liposome product thereof
|
US5849727A
(en)
|
1996-06-28 |
1998-12-15 |
Board Of Regents Of The University Of Nebraska |
Compositions and methods for altering the biodistribution of biological agents
|
EP0975370B9
(en)
|
1997-05-21 |
2004-11-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Composition and method for enhancing transport across biological membranes
|
US6329501B1
(en)
|
1997-05-29 |
2001-12-11 |
Auburn University |
Methods and compositions for targeting compounds to muscle
|
US7572582B2
(en)
|
1997-09-12 |
2009-08-11 |
Exiqon A/S |
Oligonucleotide analogues
|
US6794499B2
(en)
|
1997-09-12 |
2004-09-21 |
Exiqon A/S |
Oligonucleotide analogues
|
WO1999042091A2
(en)
|
1998-02-19 |
1999-08-26 |
Massachusetts Institute Of Technology |
Use of polycations as endosomolytic agents
|
US6683173B2
(en)
|
1998-04-03 |
2004-01-27 |
Epoch Biosciences, Inc. |
Tm leveling methods
|
JP2002523035A
(en)
|
1998-08-25 |
2002-07-30 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
49 human secreted proteins
|
US6210892B1
(en)
|
1998-10-07 |
2001-04-03 |
Isis Pharmaceuticals, Inc. |
Alteration of cellular behavior by antisense modulation of mRNA processing
|
JP2000125448A
(en)
|
1998-10-14 |
2000-04-28 |
Yazaki Corp |
Electrical junction box
|
WO2000045167A2
(en)
|
1999-01-29 |
2000-08-03 |
Avi Biopharma, Inc. |
Non-invasive method for detecting target rna
|
JP2000256547A
(en)
|
1999-03-10 |
2000-09-19 |
Sumitomo Dow Ltd |
Resin composition for heat-resistant card
|
US7084125B2
(en)
|
1999-03-18 |
2006-08-01 |
Exiqon A/S |
Xylo-LNA analogues
|
KR20020013519A
(en)
|
1999-04-08 |
2002-02-20 |
추후제출 |
Antisense Oligonucleotides Comprising Universal and/or Degenerate Bases
|
NZ514348A
(en)
|
1999-05-04 |
2004-05-28 |
Exiqon As |
L-ribo-LNA analogues
|
JP2000325085A
(en)
|
1999-05-21 |
2000-11-28 |
Masafumi Matsuo |
Pharmaceutical composition for treatment of duchenne muscular dystrophy
|
CA2374499A1
(en)
|
1999-05-24 |
2000-11-30 |
Avi Biopharma, Inc. |
Antisense to c-myc for treatment of polycystic kidney disease
|
US6303573B1
(en)
|
1999-06-07 |
2001-10-16 |
The Burnham Institute |
Heart homing peptides and methods of using same
|
US7229961B2
(en)
|
1999-08-24 |
2007-06-12 |
Cellgate, Inc. |
Compositions and methods for enhancing drug delivery across and into ocular tissues
|
EP2269654A3
(en)
|
1999-08-24 |
2011-04-13 |
Cellgate Inc. |
Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
|
US6669951B2
(en)
|
1999-08-24 |
2003-12-30 |
Cellgate, Inc. |
Compositions and methods for enhancing drug delivery across and into epithelial tissues
|
US20030104622A1
(en)
|
1999-09-01 |
2003-06-05 |
Robbins Paul D. |
Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
|
US7163695B2
(en)
|
1999-12-29 |
2007-01-16 |
Mixson A James |
Histidine copolymer and methods for using same
|
US7070807B2
(en)
|
1999-12-29 |
2006-07-04 |
Mixson A James |
Branched histidine copolymers and methods for using same
|
US20020009491A1
(en)
|
2000-02-14 |
2002-01-24 |
Rothbard Jonathan B. |
Compositions and methods for enhancing drug delivery across biological membranes and tissues
|
US6653467B1
(en)
|
2000-04-26 |
2003-11-25 |
Jcr Pharmaceutical Co., Ltd. |
Medicament for treatment of Duchenne muscular dystrophy
|
US6727355B2
(en)
|
2000-08-25 |
2004-04-27 |
Jcr Pharmaceuticals Co., Ltd. |
Pharmaceutical composition for treatment of Duchenne muscular dystrophy
|
US6559279B1
(en)
|
2000-09-08 |
2003-05-06 |
Isis Pharmaceuticals, Inc. |
Process for preparing peptide derivatized oligomeric compounds
|
US20040170955A1
(en)
|
2000-09-08 |
2004-09-02 |
Wadih Arap |
Human and mouse targeting peptides identified by phage display
|
EP1191097A1
(en)
|
2000-09-21 |
2002-03-27 |
Leids Universitair Medisch Centrum |
Induction of exon skipping in eukaryotic cells
|
WO2002038764A2
(en)
|
2000-11-10 |
2002-05-16 |
The Regents Of The University Of California |
Il-17 receptor-like protein, uses thereof, and modulation of catabolic activity of il-17 cytokines on bone and cartilage
|
WO2002063280A1
(en)
|
2001-02-06 |
2002-08-15 |
Auburn University |
Ligand sensor devices and uses thereof
|
WO2002062989A2
(en)
|
2001-02-08 |
2002-08-15 |
Sequitur, Inc. |
Methods of light activated release 0f ligands from endosomes
|
ATE437647T1
(en)
|
2001-02-16 |
2009-08-15 |
Cellgate Inc |
TRANSPORTER WITH SPACED ARGININE PARTICLES
|
US7456146B2
(en)
|
2001-05-09 |
2008-11-25 |
Ghc Research Development Corporation |
Lytic peptide prodrugs
|
CA2447052A1
(en)
|
2001-05-17 |
2002-11-21 |
Avi Biopharma, Inc. |
Combined approach to treatment of cancer using a c-myc antisense oligomer
|
US20060270003A1
(en)
|
2003-07-08 |
2006-11-30 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
JP3735292B2
(en)
|
2001-07-26 |
2006-01-18 |
三菱重工業株式会社 |
Dietary health foods and formulations
|
US6645974B2
(en)
|
2001-07-31 |
2003-11-11 |
Merck & Co., Inc. |
Androgen receptor modulators and methods for use thereof
|
US20090075377A1
(en)
|
2001-08-03 |
2009-03-19 |
Arbor Vita Corporation |
Molecular interactions in cells
|
JP2005514005A
(en)
|
2001-09-04 |
2005-05-19 |
エクシコン エ/エス |
Novel LNA compositions and uses thereof
|
CA2469336C
(en)
|
2001-12-11 |
2013-06-11 |
The Board Of Trustees Of The Leland Stanford Junior University |
Guanidinium transport reagents and conjugates
|
KR100464261B1
(en)
|
2002-01-24 |
2005-01-03 |
주식회사 파나진 |
A Novel Monomer For Synthesis of PNA Oligomer And A Process For Producing The Same
|
KR20030084444A
(en)
|
2002-04-26 |
2003-11-01 |
주식회사 파나진 |
A Novel Monomer For Synthesis of PNA Oligomer And A Process For Producing The Same
|
US7569575B2
(en)
|
2002-05-08 |
2009-08-04 |
Santaris Pharma A/S |
Synthesis of locked nucleic acid derivatives
|
WO2004043978A2
(en)
|
2002-11-05 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
|
EP1568769A4
(en)
|
2002-11-25 |
2008-08-06 |
Masafumi Matsuo |
ENA NUCLEIC ACID DRUGS MODIFYING SPLICING IN mRNA PRECURSOR
|
US7482016B2
(en)
|
2003-03-19 |
2009-01-27 |
The J. David Gladstone Institutes |
Immunogenic compositions comprising HIV-1 acetylated Tat polypeptides
|
AU2003225410A1
(en)
|
2003-03-21 |
2004-10-11 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
ES2351976T3
(en)
|
2003-04-29 |
2011-02-14 |
Avi Biopharma, Inc. |
COMPOSITIONS TO IMPROVE THE TRANSPORTATION AND ANTI-EFFECTIVE EFFECTIVENESS OF NUCLEIC ACID ANALOGS IN CELLS.
|
US7211668B2
(en)
|
2003-07-28 |
2007-05-01 |
Panagene, Inc. |
PNA monomer and precursor
|
US20050222068A1
(en)
|
2003-10-23 |
2005-10-06 |
Mourich Dan V |
Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells
|
US20050203041A1
(en)
|
2003-09-23 |
2005-09-15 |
Mourich Dan V. |
Antisense compound and method for selectively killing activated T cells
|
US7786151B2
(en)
|
2004-01-09 |
2010-08-31 |
Kinopharma, Inc. |
Therapeutic composition of treating abnormal splicing caused by the excessive kinase induction
|
US20050234002A1
(en)
|
2004-01-23 |
2005-10-20 |
Mourich Dan V |
Antisense oligomers and methods for inducing immune tolerance and immunosuppression
|
US20060078542A1
(en)
|
2004-02-10 |
2006-04-13 |
Mah Cathryn S |
Gel-based delivery of recombinant adeno-associated virus vectors
|
US7402574B2
(en)
|
2004-03-12 |
2008-07-22 |
Avi Biopharma, Inc. |
Antisense composition and method for treating cancer
|
US20050288246A1
(en)
|
2004-05-24 |
2005-12-29 |
Iversen Patrick L |
Peptide conjugated, inosine-substituted antisense oligomer compound and method
|
WO2005117928A1
(en)
|
2004-05-30 |
2005-12-15 |
Cemines, Inc. |
Compositions and methods for the treatment of skin cancer
|
ES2361325T3
(en)
|
2004-06-28 |
2011-06-16 |
The University Of Western Australia |
OLIGONUCLEÓTIDOS ANTISENTIDO TO INDUCE THE OMISSION OF EXON AND METHODS OF USE OF THE SAME.
|
CA2572151A1
(en)
|
2004-06-30 |
2006-08-24 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising a non-phosphate backbone linkage
|
CN101084002B
(en)
|
2004-09-02 |
2015-01-21 |
克格诺西有限公司 |
Improved apo e analogs and methods for their use
|
WO2006031996A2
(en)
|
2004-09-14 |
2006-03-23 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Targeting viruses using a modified sindbis glycoprotein
|
US8129352B2
(en)
|
2004-09-16 |
2012-03-06 |
Avi Biopharma, Inc. |
Antisense antiviral compound and method for treating ssRNA viral infection
|
US8357664B2
(en)
|
2004-10-26 |
2013-01-22 |
Avi Biopharma, Inc. |
Antisense antiviral compound and method for treating influenza viral infection
|
US7524829B2
(en)
|
2004-11-01 |
2009-04-28 |
Avi Biopharma, Inc. |
Antisense antiviral compounds and methods for treating a filovirus infection
|
NZ538097A
(en)
|
2005-02-07 |
2006-07-28 |
Ovita Ltd |
Method and compositions for improving wound healing
|
EP1855694B1
(en)
|
2005-02-09 |
2020-12-02 |
Sarepta Therapeutics, Inc. |
Antisense composition for treating muscle atrophy
|
BRPI0606991A2
(en)
|
2005-02-14 |
2009-08-18 |
Wyeth Corp |
methods for screening test compounds capable of antagonizing il-17f signaling, to diagnose a disorder related to increased il-17f signaling in an individual, in vitro to inhibit at least one activity associated with il-21 signaling, in vitro to inhibit at least one activity associated with il-23 signaling, to purify the natural il-17a protein, and to isolate il-17a / il-17f heterodimers substantially free of il-17a homodimers and il-17f, use of a therapeutically effective amount of an il-17f signaling antagonist, pharmaceutical composition, vaccine adjuvant, isolated antibody, isolated il-17f and il-17a proteins, and il-17a / il-heterodimer. 17f
|
US20090312532A1
(en)
|
2005-04-22 |
2009-12-17 |
Van Deutekom Judith Christina |
Modulation of exon recognition in pre-mrna by interfering with the binding of sr proteins and by interfering with secodary rna structure
|
JP2008539209A
(en)
|
2005-04-26 |
2008-11-13 |
カリヨン−シーティーティー リミテッド |
Diagnostic and therapeutic agents
|
WO2008005002A1
(en)
|
2006-06-30 |
2008-01-10 |
Oligos Ets. Inc. |
Compositions and methods for the treatment of muscle wasting
|
US7790694B2
(en)
|
2005-07-13 |
2010-09-07 |
Avi Biopharma Inc. |
Antisense antibacterial method and compound
|
US8067571B2
(en)
|
2005-07-13 |
2011-11-29 |
Avi Biopharma, Inc. |
Antibacterial antisense oligonucleotide and method
|
EP1915161B1
(en)
|
2005-07-13 |
2017-04-26 |
Sarepta Therapeutics, Inc. |
Antisense antibacterial method and compound
|
US8524676B2
(en)
|
2005-09-08 |
2013-09-03 |
Sarepta Therapeutics, Inc. |
Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds
|
US8329668B2
(en)
|
2005-09-08 |
2012-12-11 |
Avi Biopharma, Inc. |
Antisense antiviral compound and method for treating picornavirus infection
|
CA2624081C
(en)
|
2005-09-29 |
2014-09-16 |
Medimmune, Inc. |
Method of identifying membrane ig specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
|
AU2006311586A1
(en)
|
2005-11-08 |
2007-05-18 |
Avi Biopharma, Inc. |
Immunosuppression compound and treatment method
|
US8501704B2
(en)
|
2005-11-08 |
2013-08-06 |
Sarepta Therapeutics, Inc. |
Immunosuppression compound and treatment method
|
KR101789603B1
(en)
|
2005-11-10 |
2017-11-21 |
더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 |
Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease
|
WO2007103529A2
(en)
|
2006-03-07 |
2007-09-13 |
Avi Biopharma, Inc. |
Antisense antiviral compound and method for treating arenavirus infection
|
US8785407B2
(en)
|
2006-05-10 |
2014-07-22 |
Sarepta Therapeutics, Inc. |
Antisense antiviral agent and method for treating ssRNA viral infection
|
WO2008036127A2
(en)
|
2006-05-10 |
2008-03-27 |
Avi Biopharma, Inc. |
Oligonucleotide analogs having cationic intersubunit linkages
|
EP2019011A1
(en)
|
2006-05-17 |
2009-01-28 |
Svetlana Anatolevna Sokolova |
Transport means
|
DK2049664T3
(en)
|
2006-08-11 |
2012-01-02 |
Prosensa Technologies Bv |
Single-stranded oligonucleotides, complementary to repetitive elements, for the treatment of DNA repetitive instability-associated disorders
|
US20080199961A1
(en)
|
2006-08-25 |
2008-08-21 |
Avi Biopharma, Inc. |
ANTISENSE COMPOSITION AND METHOD FOR INHIBITION OF miRNA BIOGENESIS
|
US20080267978A1
(en)
|
2006-08-28 |
2008-10-30 |
Mary Zutter |
Anti-angiogenic targets for cancer therapy
|
EP2066812A4
(en)
|
2006-09-21 |
2010-04-28 |
Univ Rochester |
Compositions and methods related to protein displacement therapy for myotonic distrophy
|
FR2908999B1
(en)
|
2006-11-29 |
2012-04-27 |
Biomerieux Sa |
NOVEL DRUG FOR THE INHIBITION, PREVENTION OR TREATMENT OF RHEUMATOID ARTHRITIS.
|
EP1938802A1
(en)
|
2006-12-22 |
2008-07-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Interfering RNAs targeting pro-inflammatory cytokines
|
ES2694726T3
(en)
|
2007-06-29 |
2018-12-26 |
Sarepta Therapeutics, Inc. |
Tissue specific peptide conjugates and methods
|
US20100016215A1
(en)
|
2007-06-29 |
2010-01-21 |
Avi Biopharma, Inc. |
Compound and method for treating myotonic dystrophy
|
CA2693742A1
(en)
|
2007-07-12 |
2009-01-15 |
Prosensa Technologies B.V. |
Molecules for targeting compounds to various selected organs, tissues or tumor cells
|
US20110300154A1
(en)
|
2007-08-21 |
2011-12-08 |
Children's Medical Center Corporation |
Treatment of airway hyperreactivity
|
PT2203173E
(en)
|
2007-10-26 |
2016-03-15 |
Academisch Ziekenhuis Leiden |
Means and methods for counteracting muscle disorders
|
US8076476B2
(en)
|
2007-11-15 |
2011-12-13 |
Avi Biopharma, Inc. |
Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
|
BR122019021332A8
(en)
|
2007-11-15 |
2022-12-06 |
Avi Biopharma Inc |
MORPHOLIN OLIGOMER SYNTHESIS PROCESS
|
US8299206B2
(en)
|
2007-11-15 |
2012-10-30 |
Avi Biopharma, Inc. |
Method of synthesis of morpholino oligomers
|
US7989608B2
(en)
|
2007-12-28 |
2011-08-02 |
Avi Biopharma Inc. |
Immunomodulatory agents and methods of use
|
WO2009127230A1
(en)
|
2008-04-16 |
2009-10-22 |
Curevac Gmbh |
MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
|
EP2119783A1
(en)
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
|
US20110130346A1
(en)
|
2008-05-30 |
2011-06-02 |
Isis Innovation Limited |
Peptide conjugates for delvery of biologically active compounds
|
US8084601B2
(en)
|
2008-09-11 |
2011-12-27 |
Royal Holloway And Bedford New College Royal Holloway, University Of London |
Oligomers
|
EP3133160B1
(en)
|
2008-10-24 |
2018-12-12 |
Sarepta Therapeutics, Inc. |
Exon skipping compositions for dmd
|
PT2607484E
(en)
|
2008-10-27 |
2016-03-09 |
Academisch Ziekenhuis Leiden |
Methods and means for efficient skipping of exon 45 in duchenne muscular dystrophy pre-mrna
|
JP5645840B2
(en)
|
2008-12-02 |
2014-12-24 |
株式会社Wave Life Sciences Japan |
Method for synthesizing phosphorous atom-modified nucleic acid
|
EP2376633A1
(en)
|
2008-12-17 |
2011-10-19 |
AVI BioPharma, Inc. |
Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
|
DK2417257T3
(en)
|
2009-04-10 |
2016-06-06 |
Ass Inst De Myologie |
TRICYCLO DNA ANTISENSE OLIGONUCLEOTIDES, COMPOSITIONS, AND PROCEDURES FOR THE TREATMENT OF DISEASE
|
US20120046342A1
(en)
|
2009-04-24 |
2012-02-23 |
Prosensa Technologies B.V. |
Oligonucleotide comprising an inosine for treating dmd
|
US20110269665A1
(en)
|
2009-06-26 |
2011-11-03 |
Avi Biopharma, Inc. |
Compound and method for treating myotonic dystrophy
|
MX342945B
(en)
|
2009-07-06 |
2016-10-18 |
Ontorii Inc * |
Novel nucleic acid prodrugs and methods use thereof.
|
ES2586683T3
(en)
|
2009-09-16 |
2016-10-18 |
Wave Life Sciences Japan, Inc. |
Novel protective group to synthesize RNA and derivatives thereof
|
KR20230137491A
(en)
|
2009-11-12 |
2023-10-04 |
더 유니버시티 오브 웨스턴 오스트레일리아 |
Antisense Molecules and Methods for Treating Pathologies
|
US9238042B2
(en)
|
2010-05-13 |
2016-01-19 |
Sarepta Therapeutics, Inc. |
Antisense modulation of interleukins 17 and 23 signaling
|
KR102182663B1
(en)
|
2010-05-28 |
2020-11-25 |
사렙타 쎄러퓨틱스, 인코퍼레이티드 |
Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
|
TWI541024B
(en)
|
2010-09-01 |
2016-07-11 |
日本新藥股份有限公司 |
Antisense nucleic acid
|
JP5868324B2
(en)
|
2010-09-24 |
2016-02-24 |
株式会社Wave Life Sciences Japan |
Asymmetric auxiliary group
|
US9078911B2
(en)
|
2011-02-08 |
2015-07-14 |
The Charlotte-Mecklenburg Hospital Authority |
Antisense oligonucleotides
|
US9161948B2
(en)
*
|
2011-05-05 |
2015-10-20 |
Sarepta Therapeutics, Inc. |
Peptide oligonucleotide conjugates
|
WO2012150960A1
(en)
*
|
2011-05-05 |
2012-11-08 |
Avi Biopharma, Inc. |
Peptide oligonucleotide conjugates
|
US9607308B2
(en)
|
2011-06-29 |
2017-03-28 |
American Express Travel Related Services Company, Inc. |
Spend based digital ad targeting and measurement
|
EP2581448B1
(en)
|
2011-10-13 |
2015-01-28 |
Association Institut de Myologie |
Tricyclo-phosphorothioate DNA
|
WO2013082551A1
(en)
|
2011-11-30 |
2013-06-06 |
Sarepta Therapeutics, Inc. |
Induced exon inclusion in spinal muscle atrophy
|
KR102071729B1
(en)
|
2011-12-28 |
2020-01-31 |
니뽄 신야쿠 가부시키가이샤 |
Antisense nucleic acid
|
NZ627896A
(en)
|
2012-01-27 |
2016-11-25 |
Biomarin Technologies B V |
Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
|
DE102012101676A1
(en)
|
2012-02-29 |
2013-08-29 |
Klaus-Dieter Rösler |
Method and device for processing forms with a data processing system
|
JP6460983B2
(en)
|
2012-07-03 |
2019-01-30 |
バイオマリン テクノロジーズ ベー.フェー. |
Oligonucleotides for the treatment of patients with muscular dystrophy
|
US9598458B2
(en)
|
2012-07-13 |
2017-03-21 |
Wave Life Sciences Japan, Inc. |
Asymmetric auxiliary group
|
SG10201912895PA
(en)
|
2012-07-13 |
2020-02-27 |
Wave Life Sciences Ltd |
Chiral control
|
KR20200143739A
(en)
|
2012-12-20 |
2020-12-24 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
Improved exon skipping compositions for treating muscular dystrophy
|
KR20230074606A
(en)
|
2013-03-14 |
2023-05-30 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
Exon skipping compositions for treating muscular dystrophy
|
CN110218727A
(en)
|
2013-03-14 |
2019-09-10 |
萨勒普塔医疗公司 |
For treating the exon skipping composition of muscular dystrophy
|
US20140329762A1
(en)
*
|
2013-03-15 |
2014-11-06 |
Sarepta Therapeutics, Inc. |
Compositions for treating muscular dystrophy
|
CA2922838A1
(en)
*
|
2013-09-05 |
2015-03-12 |
Sarepta Therapeutics, Inc. |
Antisense-induced exon2 inclusion in acid alpha-glucosidase
|
JPWO2015108048A1
(en)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
Chiral nucleic acid adjuvant and antitumor agent having antitumor activity
|
WO2015108046A1
(en)
|
2014-01-15 |
2015-07-23 |
株式会社新日本科学 |
Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
|
US10144933B2
(en)
|
2014-01-15 |
2018-12-04 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
|
SG11201605782UA
(en)
|
2014-01-16 |
2016-08-30 |
Wave Life Sciences Ltd |
Chiral design
|
ES2710802T3
(en)
|
2014-03-12 |
2019-04-26 |
Nat Center Neurology & Psychiatry |
Antisense nucleic acid
|
CA2951221A1
(en)
|
2014-06-17 |
2015-12-23 |
Nippon Shinyaku Co., Ltd. |
Antisense nucleic acids
|
US20160130567A1
(en)
|
2014-11-02 |
2016-05-12 |
Arcturus Therapeutics, Inc. |
Messenger una molecules and uses thereof
|
MA43072A
(en)
|
2015-07-22 |
2018-05-30 |
Wave Life Sciences Ltd |
COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
|
IL258230B
(en)
|
2015-10-09 |
2022-09-01 |
Wave Life Sciences Ltd |
Oligonucleotide compositions and methods thereof
|
EA201890908A1
(en)
|
2015-10-09 |
2018-10-31 |
Сарепта Терапьютикс, Инк. |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUSCULAR DYSTROPHY OF YOUNG AND SIMILAR DISORDERS
|
MA45270A
(en)
|
2016-05-04 |
2017-11-09 |
Wave Life Sciences Ltd |
COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
|
MA45290A
(en)
|
2016-05-04 |
2019-03-13 |
Wave Life Sciences Ltd |
PROCESSES AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS
|
RS63610B1
(en)
*
|
2016-12-19 |
2022-10-31 |
Sarepta Therapeutics Inc |
Exon skipping oligomer conjugates for muscular dystrophy
|